Clinical Trial

Dexrazoxane to Protect Against Hemorrhagic STEMI

Study acronym: SHIELD-MI
Completed Phase 2
View on ClinicalTrials.gov →
Summary
This Phase Ila trial evaluates whether the intravenous administration of Dexrazoxane can reduce permanent heart muscle damage in patients undergoing standard stent procedures (PCI) for a severe heart attack (STEMI).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-03-26; most recent amendment 2026-05-21.
Trial Details
NCT Number NCT07502521
Lead Sponsor Rohan Dharmakumar
Conditions Acute Myocardial Infarction (AMI)
Enrollment 50 participants
Start Date 2025-08-30
Primary Completion 2026-02-15 (estimated)
Study Completion 2026-03-16 (estimated)
Updated on ClinicalTrials.gov 2026-05-26